Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Asia Healthcare Industry Digest.
Press releases published on May 6, 2025
Keros Therapeutics Reports Recent First Quarter 2025 Financial Results
GlobeNewswire
·
May 6, 2025
LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients …
Voyager Reports First Quarter 2025 Financial and Operating Results
GlobeNewswire
·
May 6, 2025
– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg – – Recent Voyager data on VY7523 and VY1706 presented at AD/PD™ …
Lantheus Announces Sale of SPECT Business to SHINE Technologies
GlobeNewswire
·
May 6, 2025
Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business SHINE will acquire products TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite® BEDFORD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lantheus …
Standard BioTools Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 6, 2025
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 …
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 6, 2025
CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on May 1, 2025, it awarded an …
CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3
GlobeNewswire
·
May 6, 2025
-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated safety profile; presentation …
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 6, 2025
WATERTOWN, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic …
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
GlobeNewswire
·
May 6, 2025
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business highlights. “The completion of our BLA submission for …
Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update
GlobeNewswire
·
May 6, 2025
First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million Reaffirm 2025 Financial Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and …
Day One Reports First Quarter 2025 Financial Results and Corporate Progress
GlobeNewswire
·
May 6, 2025
OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash, cash equivalents and short-term investments Company …
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
GlobeNewswire
·
May 6, 2025
NEWTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the …
Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 6, 2025
PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 ~$1.1 Billion in Cash, Cash Equivalents and Investments …
Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 6, 2025
Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible resets and insurance changes, and excluding the non-recurring …
SOUND Behavioral Health Launches “Orange Door” Campaign for Mental Health Awareness Month
GlobeNewswire
·
May 6, 2025
SEATTLE, May 06, 2025 (GLOBE NEWSWIRE) -- This May, in recognition of Mental Health Awareness Month, SOUND Behavioral Health is proud to launch the “Orange Door” campaign—a bold new initiative designed to raise awareness around the growing need for mental …
Late-Breaking Interim STENOVA Data Presented at Digestive Disease Week® 2025 Demonstrate Potential of AGMB-129 in Fibrostenosing Crohn’s Disease
GlobeNewswire
·
May 6, 2025
Antwerp, Belgium, May 6, 2025 – Agomab Therapeutics NV (“Agomab”) today announced late-breaking interim data from the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGF-β …
Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering
GlobeNewswire
·
May 6, 2025
HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the closing of its previously announced …
Annual NMDP(SM) Gala in New York City Raises Over a Half Million Dollars, Enabling More Patients to Receive Life-Saving Cell Therapy
GlobeNewswire
·
May 6, 2025
MINNEAPOLIS, May 06, 2025 (GLOBE NEWSWIRE) -- NMDPSM hosted its annual gala in New York on Thursday, May 1, raising $525,000-- funds which will support patient financial assistance and innovative cell therapy research to improve post-transplant outcomes …
Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq
GlobeNewswire
·
May 6, 2025
CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R…
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
GlobeNewswire
·
May 6, 2025
New York, USA, May 06, 2025 (GLOBE NEWSWIRE) -- Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight Angioedema is a rapid swelling of the deeper …
R3 Stem Cell Wins 2025 Award for Leading Innovators in Regenerative Cell Therapy
EIN Presswire
·
May 6, 2025
SCOTTSDALE, AZ, UNITED STATES, May 5, 2025 /EINPresswire.com/ -- R3 Stem Cell has won the 2025 Award for Leading Innovators in Regenerative Cell Therapy. As the global leader in stem cell and exosome treatments, this makes the fifth straight year that R3 …